Douglas E. Giordano
CIK 1431552 · last filed 2026-06-22
Douglas E. Giordano is a corporate insider who has filed 8 SEC Form 4 insider transactions across 5 companies since 2013. The most recent filing, for KARD, was dated Jun 22, 2026. Across all open-market trades the lifetime net is +$130.0K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $666.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ZTS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
235 EAST 42ND STREET
NEW YORK, NY 10017
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KARD | Director | 20,706 | $12.64 | $261.7K | $0 | 1 | 2026-06-22 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Director | 13,743 | $44.96 | $617.9K | $0 | 3 | 2024-06-07 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Director | — | $18.07 | — | $0 | 1 | 2021-06-14 |
| VTRS | Director | — | $19.85 | — | $0 | 1 | 2020-11-16 |
| ZTS | Director | 5,000 | $80.91 | $404.5K | $130.0K | 1 | 2013-02-08 |
Recent Filings
8 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-22 | KARD | Grant (A) | +20,706 | $0 | EDGAR |
| 2024-08-05 | — | Disp (D) | −13,743 | $0 | |
| 2024-06-07 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Grant (A) | +10,461 | $0 | EDGAR |
| 2023-06-09 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Grant (A) | +3,282 | $0 | EDGAR |
| 2022-06-16 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-14 | Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-11-16 | VTRS | — | — | $0 | EDGAR |
| 2013-02-08 | ZTS | Buy (P) | +5,000 | $130.0K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).